Raptor Pharmaceuticals Corp.
(NASDAQ : RPTP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.13%53.920.9%$1395.93m
JNJJohnson & Johnson 0.85%180.990.7%$1263.76m
BMYBristol-Myers Squibb Co. -1.86%76.151.0%$1200.63m
MRKMerck & Co., Inc. 0.77%93.020.7%$1171.65m
ABBVAbbVie, Inc. -0.36%150.031.9%$1112.27m
LLYEli Lilly & Co. 3.15%323.341.1%$1017.85m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.15%143.400.0%$499.78m
AZNAstraZeneca Plc 1.05%67.401.0%$486.39m
NVSNovartis AG 0.22%91.460.2%$258.15m
GSKGlaxoSmithKline Plc -0.83%44.050.2%$255.09m
VERUVeru, Inc. 1.50%12.830.0%$252.54m
SIGASIGA Technologies, Inc. 41.91%13.680.0%$209.92m
HZNPHorizon Therapeutics Plc 4.69%94.845.4%$209.26m
SGENSeagen Inc. 2.12%141.395.7%$188.92m
NVONovo Nordisk A/S 1.07%107.740.1%$184.03m

Company Profile

Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington's Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.